Back

Decrease of ECG hypertrophy indices during mavacamten treatment in obstructive hypertrophic cardiomyopathy

19 May 2025 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Robert Sepp

University of Szeged, Szeged (Hungary)

6 More presentations in this session

Presentation thumbnail
Characterisation of interrelations among myocardial work parameters in patients with hypertrophic cardiomyopathy: differences between non-obstructive and obstructive disease
Doctor A. Kormanyos (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
The role of stress echocardiography to unmask latent LVOT obstruction in hypertrophic cardiomyopathy
Doctor D. Faro (Catania, IT)
Abstract Slides Video
Presentation thumbnail
Long-term efficacy of mavacamten on cardiac structure and function in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial
Doctor Z. Tian (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
The influence of genotype on the phenotype and prognosis of patients with hypertrophic cardiomyopathy
Miss I. Conde (Braga, PT)
Abstract Slides Video
Presentation thumbnail
Examining ECG's performance as a screening method for hypertrophic cardiomyopathy: phenotypic correlations and evaluation
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2025

19 May 2025 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Effect of Mavacamten on left ventricular diastolic function and left atrial function in obstructive hypertrophic cardiomyopathy
thumbnail
Congress Session
Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy
thumbnail
Congress Presentation
Electrocardiographic markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources